The development of tyrosine kinase inhibitors (TKIs) capable of targeting BCR/Abl kinase activity substantially improved CML prognosis, with long‐term control of disease and extended patient survival [2]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.